Hyderabad: After a company such as the Dr.
Reddy Laboratory, Natco Pharma and Optimus Pharma, now Hyderabad-based pharmaceutical companies, Aurobindo Pharma, have launched the 200mg Molnupiravir anti-virus drug.
Aurobindo Pharma on Thursday said the Molnaflu will be valued at around 50 per capsule, which translates to around 2,000 for a five-day regimen package of 40 capsules that the company said that for the licensed version of Molnupiravir he has integration of retreat with manufacturing fire at home, which complements with Stronger controls on quality systems and supply chains.
“This product will be produced at a manufacturing facility company in India approved by the global watchdog including USFDA and UKMHRA.
The company has an adequate capacity to meet global demand in more than 100 LMI countries for products,” he said.
Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy said the company is committed to increasing access to Molnupiravir for patients in need in the partner area.
Earlier last year, Aurobindo has signed a bi-lateral non-exclusive voluntary license agreement with Merck Sharpe Dohme, Singapore, Merck & Co (US) subsidiary for producing and supplying Molnupiravir to more than 100 low and medium-sized income countries, including India.
This drug has just been given approval for limited use in emergency situations by standard drug control organizations (CDSCO) for the treatment of covid-19-19 patients who have a level of SP02 more than 93% and at high risk of disease development including inpatient or death.
Hyderabad: After a company such as the Dr.
Reddy Laboratory, Natco Pharma and Optimus Pharma, now Hyderabad-based pharmaceutical companies, Aurobindo Pharma, have launched the 200mg Molnupiravir anti-virus drug.
Aurobindo Pharma on Thursday said the Molnaflu will be valued at around 50 per capsule, which translates to around 2,000 for a five-day regimen package of 40 capsules that the company said that for the licensed version of Molnupiravir he has integration of retreat with manufacturing fire at home, which complements with Stronger controls on quality systems and supply chains.
“This product will be produced at a manufacturing facility company in India approved by the global watchdog including USFDA and UKMHRA.
The company has an adequate capacity to meet global demand in more than 100 LMI countries for products,” he said.
Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy said the company is committed to increasing access to Molnupiravir for patients in need in the partner area.
Earlier last year, Aurobindo has signed a bi-lateral non-exclusive voluntary license agreement with Merck Sharpe Dohme, Singapore, Merck & Co (US) subsidiary for producing and supplying Molnupiravir to more than 100 low and medium-sized income countries, including India.
This drug has just been given approval for limited use in emergency situations by standard drug control organizations (CDSCO) for the treatment of covid-19-19 patients who have a level of SP02 more than 93% and at high risk of disease development including inpatient or death.